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Re: ‘Galectin-3, Carotid Plaque Vulnerability, and Potential
Effects of Statin Therapy’
We read with interest in our vascular department the article
by Kadoglou et al.1 Although it is a novel marker to be
studied in the setting of carotid arteries, there are consid-
erable fallacies in the aim, methodology, and the conclu-
sions drawn. We wish to draw attention to only some
salient ones in this communication. The introduction with a
reference states that “Galectin-3, propagates vascular
inﬂammation by inducing the expression of pro-
inﬂammatory mediators in macrophages and the migra-
tion of monocytes into vascular walls”. However the
conclusion states that “the ﬁndings support the hypothesis
that galectin-3 is predominantly an anti-inﬂammatory
mediator in advanced carotid plaques”.
The primary or secondary aim of the study does not
involve the grey-scale median; however, it is extensively
used in the results and discussion. There was no mention of
an ethical approval to study the plaque. Although the
methodology suggests that Pearson’s correlation test was
done, the results do not reveal them.
The authors attribute their results to the dual function of
pro- and anti-inﬂammatory roles of the study marker sup-
ported by one animal study.
Overall, this study although interesting does not have a
robust and clear message due to its intrinsic pitfalls. The
authors however have been honest, declaring the limita-
tions. This marker does have potential for more research
based on the association with carotid plaque.
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j.ejvs.2015.02.010Re: ‘Response to Letter to the Editor on “Galectin-3,
Carotid Plaque Vulnerability, and Potential Effects of Statin
Therapy”’
We read with interest the letter by Sharma et al. regarding
our study “Galectin 3, carotid plaque vulnerability, and
potential effects of statin therapy”.1 We strongly disagree
with the alleged fallacies of our study, as described by the
authors of the letter.
Regarding the biological role of galectin-3 in atheroscle-
rosis, there are conﬂicting reports in the literature. Galectin-
3 has been increasingly recognized as an important modu-
lator of several biological functions, by interacting with
several molecules inside and outside the cell, and exerts
various and contrasting effects according to its location,
type, and site of damage.2 The contributory role of galectin-
3 in both the acceleration and inhibition of atherosclerosis
has been described in animal studies.3,4 Limited data exist
regarding the role of galectin-3 in carotid plaque destabili-
zation. Our study was designed to investigate the relation-
ship between galectin-3 and carotid plaque embolization
manifested by ipsilateral neurological symptoms. For all the
abovementioned reasons we mentioned both theories
about the role of galectin-3 in the “Introduction” (the
phrase used by the authors of the letter, “galectin-3 prop-
agates vascular inﬂammation”, skews what was actually
written: “galectin-3 has been reported to propagate
vascular inﬂammation”).
Moreover, as stated in the “Introduction”, the primary
goal of the study was also “to investigate the relationship
between galectin-3 and an ultrasound index of carotid
plaque vulnerability”, namely the Gray Scale Median (GSM).
The GSM is a uniformly accepted index of carotid plaque
echogenicity and helps in identifying vulnerable plaques, as
explained in the “Methods” section.
Regarding ethical approval, written informed consent
from each patient was obtained before enrollment and all
procedures were performed according to the principles of
the Declaration of Helsinki, and were approved by the
hospital’s human ethics committee, as clearly stated in the
“Methods”.
The study, despite some limitations, which are carefully
and extensively reported in the “Discussion”, is the ﬁrst to
evaluate galectin-3 in human carotid plaques in relation to
clinical and ultrasonographic criteria of plaque vulnerability.
The ﬁndings lean towards the hypothesis that galectin-3 is
predominantly an anti-inﬂammatory mediator in advanced
carotid plaques. Regarding the fact that galectin-3 is well
validated and that there is expanding use in several cardi-
ological diseases, we agree with Sharma et al. that galectin-
3 has the potential to be further researched with regard to
the association with carotid plaques.
